Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emtora Presents Phase Ib Data in Low Grade Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Cancer Prevention & Research Institute of Texas","pharmaFlowCategory":"D","amount":"$19.9 million","upfrontCash":"Undisclosed","newsHeadline":"Emtora Biosciences Receives $16.9M Grant from the Cancer Prevention & Research Institute of Texas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Biodexa Pharmaceuticals","pharmaFlowCategory":"D","amount":"$41.5 million","upfrontCash":"Undisclosed","newsHeadline":"Biodexa Enters Into Exclusive License to eRapa\u2122, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2024","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Emtora Biosciences

    Menu

    Emtora Biosciences

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Emtora Biosciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)

              Details:

              Under the agreement, Biodexa gain rights to develop, manufacture, commercialize and otherwise advance the clinical potential of eRapa, a proprietary oral tablet formulation of rapamycin and an mTOR inhibitor, for the treatment of Familial Adenomatous Polyposis.

              Lead Product(s): Sirolimus

              Therapeutic Area: Genetic Disease Product Name: eRapa

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Biodexa Pharmaceuticals

              Deal Size: $41.5 million Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement April 26, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Emtora Biosciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Emtora Biosciences Receives $16.9M Grant from the Cancer Prevention & Research Institute of Texas

              Details:

              Emtora plans to use the CPRIT award to complete a multicenter, randomized, placebo-controlled Phase 3 trial of eRapa (rapamycin) in patients with FAP. Patients with FAP are predisposed to the development of hundreds or even thousands of polyps in their gastrointestinal tract.

              Lead Product(s): Sirolimus

              Therapeutic Area: Oncology Product Name: eRapa

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Cancer Prevention & Research Institute of Texas

              Deal Size: $19.9 million Upfront Cash: Undisclosed

              Deal Type: Funding August 19, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Emtora Biosciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Emtora Presents Phase Ib Data in Low Grade Prostate Cancer

              Details:

              In patients with low-grade PCa, treatment with low dose eRapa was found to be safe and well-tolerated.

              Lead Product(s): Sirolimus

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 04, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY